Plain-English translation of NCT05916755 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is looking for biological markers—signs in your tumor cells, blood, and other samples—that can predict whether you'll respond well to (an immune checkpoint inhibitor) combined with . Researchers will study your samples using advanced genetic and imaging techniques to understand what makes the treatment work for some people but not others, and to create a personalized prediction of how well the treatment might work for you.
Not all patients with triple negative breast cancer benefit equally from immunotherapy combined with , and the treatment can cause serious side effects. This trial aims to develop tests that can predict ahead of time who is most likely to respond, so doctors can tailor treatment more effectively and avoid unnecessary toxicity.
You likely qualify if…
You likely don't qualify if…
You will receive , and depending on your treatment plan, you may also receive (an immune-boosting medication). Throughout your treatment, you will undergo multiple sample collections: tumor biopsies before and after , blood draws at baseline and during treatment, and stool and saliva samples. You will also have breast MRI scans. Researchers will analyze these samples using genetic sequencing and imaging analysis to identify patterns that predict how well you respond to treatment.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Spain